Patients and study design
malignancy, bleeding, allergy, ulcer
BLEEDING, ALLERGY, ULCER, CONCOMITANT DISEASE
Initial screening of patients aged ≥ 14 years who were diagnosed positive for If the subject failed the initial treatment, the patient was recommended for the remedial treatment after 6 months of outpatient follow-up. Patients in group A who failed The detailed exclusion criteria used were as follows: (1) pregnant or lactating women; (2) with severe concomitant disease, malignancy; (3) history of allergy to the study drug; (4) PPI or antibiotics administered within the previous month; (5) bleeding from a severe ulcer; (6) patients previously treated with anti-This clinical trial study was reviewed and approved by the Ethics Committee of the Second Affiliated Hospital of Hainan Medical University (No. LW2021038). A written informed consent was obtained from all the participants and also from legal guardians of those participants whose age was below 16 years of age. In addition, this study was conducted in accordance with the Declaration of Helsinki and other relevant regulations. This single-center, open-label, noninferiority, randomized controlled trial has been registered with the China Clinical Trials Registry (